Editorial Videos

Ankit Jain, CEO, Co-Founder, Infinitus, discusses how AI-native patient access infrastructure appears to be less about replacing care teams and more about eliminating the friction between diagnosis and therapy initiation.

Matthew Turner, President of Patient Affordability, Paysign, discusses Paysign's approach to measuring copay program value in an effort to move beyond simple redemption counts toward a more complete picture of patient adherence.

In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing manufacturers toward more sophisticated, partnership-driven program designs.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, mentions how eClinical Solutions positioned its elluminate platform as part of an effort to help sponsors meet heightened evidence and oversight demands.

New technologies are impacting the speed-to-therapy within hub services.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical development appearing to be part of a broader effort to strengthen trial evidence.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering the scientific bar.

Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.

In the second part of his conversation with Pharmaceutical Executive, Ajna Biosciences CEO Joel Stanley explains the complexities of getting a botanical drug approved.

In this Pharmaceutical Executive Academy discussion, Najat Khan, PhD, CEO of Recursion Pharmaceuticals and former chief data science officer at J&J, explores the intersection of AI, pharma, and patient care — and the strategic pivots necessary to drive measurable and lasting gains across the value chain.

Ajna Biosciences CEO Joel Stanley discusses the differences between botanical drugs and botanically-derived drugs.

Joseph Kleiman examines how Trump Rx could pressure pharmacy benefit managers and retailers to increase transparency and affordability, while cautioning that its long-term impact will depend on price consistency.

In the final part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses the challenges that pharma faces when marketing direct-to-consumers.

Buzz Health President Joseph Kleiman discusses how TrumpRx is reshaping drug price transparency, highlighting the benefits of early price visibility for consumers alongside the operational challenges of fluctuating costs, consistency and potential.

Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects.

In the second part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses how pharma marketing teams decide who to target with advertising campaigns.

Jay Bregman, CEO and co-founder of Andel, discusses how pharmaceutical companies and digital health platforms may need to rethink commercialization strategies, shifting away from costly mass-market advertising toward employer-focused distribution models.

Sandy Donaldson discusses how pharma companies are developing precise marketing strategies for the modern world.

Jay Bregman, CEO and co-founder of Andel discusses how FDA’s planned action against non-FDA-approved GLP-1 products could reshape competition in obesity and diabetes care.

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, and streamline analytics.

Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success requires a strong vision, hands-on leadership, and a talented staff.